Julie Dewey
Chief IR and Communications Officer
Replay available
Orthofix Medical Inc. (NASDAQ: OFIX) Q2 2026 earnings conference call, held 2026-08-05. Replay captured from the company's public earnings webcast.

Chief IR and Communications Officer
President and Chief Executive Officer
Chief Financial Officer
Analyst, Stifel
Analyst, Canaccord Genuity
Thank you for standing by. At this time, I would like to welcome everyone to the OrthoFix second quarter 2026 earnings call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time, simply press star followed by the number one on your telephone keypad. If you would like to go draw your question, press star one again. Thank you. I would now like to turn the call over to Julie Dewey. Thank you and good morning, everyone. Welcome to OrthoFix's second quarter 2026 earnings call. I'm Julie Dewey, OrthoFix's Chief IR and Communications Officer. Joining me today are President and Chief Executive Officer Massimo Calafiore and Chief Financial Officer Julie Andrews. Earlier today, OrthoFix released its financial results for the second quarter and did June 30th, 2026. A copy of the press release and supplemental presentation are available on our investor relations website and a replay of this call will be posted shortly after we conclude. Before we begin, please note that our remarks include forward-looking statements. These statements involve risks and uncertainties and actual results may differ materially. All statements other than those of historical facts are forward-looking statements. We do not undertake any obligation to revise or update such forward-looking statements. Factors that could cause actual results to differ materially are discussed in our most recent filings with the SEC and may be included in our future filings with the SEC. We will also reference certain non-GAAP financial measures during today's call, including certain growth rates presented on a pro forma constant currency basis and excluding discontinued M6 artificial...